Stay updated with breaking news from Eric Roeland. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention
Jaguar Health Reports Third Quarter 2023 Financial Results
256-patient enrollment target met plus 11% over-enrollment; Primary endpoint based on patient reported outcomes from study expected in October 2023SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2023 / Jaguar
Primary endpoint based on patient reported outcomes from study expected in October 2023With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described
Jaguar Completes Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea Primary endpoint based on patient reported... | May 9, 2023